RJA
MTACU

Raymond James & Associates’s MedTech Acquisition Corporation Unit MTACU Stock Holding History

Raymond James & Associates’s Portfolio MTACU Stock Details MTACU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-16,000
Closed -$160K – 4300
2021
Q2 		$160K Sell
16,000
-15,500
-49% -$157K ﹤0.01% 3741
2021
Q1 		$317K Sell
31,500
-5,500
-15% -$58.5K ﹤0.01% 3329
2020
Q4 		$389K Buy
+37,000
New +$386K ﹤0.01% 2975

Other funds holding MTACU

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Raymond James & Associates's MTACU Position: Q3 2021 in Review

Raymond James & Associates sold out of MedTech Acquisition Corporation Unit (MTACU) in Q3 2021, closing a stake of 16,000 shares — an estimated $160K sold.

Raymond James & Associates first reported a position in MTACU in Q4 2020 and held it in 3 quarters. The position peaked at $389K in Q4 2020. 20 funds tracked by Wall St. Rank hold MTACU as of Q3 2021.

  • Raymond James & Associates reported no remaining MedTech Acquisition Corporation Unit position as of Q3 2021 after selling out during the quarter.
  • Raymond James & Associates sold 16,000 MedTech Acquisition Corporation Unit shares in Q3 2021, an estimated $160K.
  • Raymond James & Associates first reported a position in MedTech Acquisition Corporation Unit in Q4 2020 and held it in 3 quarters.
  • Raymond James & Associates's MedTech Acquisition Corporation Unit position peaked at $389K in Q4 2020.
  • 20 funds tracked by Wall St. Rank held MedTech Acquisition Corporation Unit as of Q3 2021.

Based on Raymond James & Associates's 13F filing for Q3 2021, filed 2 Nov 2021.